Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Metadata
Title
Ornithine transcarbamoylase deficiency presenting with acute liver failure
Authors
Ahlam Mustafa
Joe T. R. Clarke
Publication date
01-08-2006
Publisher
Kluwer Academic Publishers
Published in
Journal of Inherited Metabolic Disease / Issue 4/2006
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-006-0303-2

Other articles of this Issue 4/2006

Journal of Inherited Metabolic Disease 4/2006 Go to the issue

Original Article

Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation

Original Article

Maple syrup urine disease: Favourable effect of early diagnosis by newborn screening on the neonatal course of the disease

Short Report

Dietary intervention and oxidative phosphorylation capacity

Short Report

Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler–Scheie patient

Original Article

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

Original Article

Seven cases of Pompe disease from Greece

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits